ICLIO Grand Rounds Program

Share: Share on FacebookTweet about this on TwitterShare on LinkedInEmail this to someone

The ICLIO Grand Rounds is a personalized learning initiative for the multidisciplinary cancer care team designed to deliver evidence-based information on the latest developments in the use of cancer immunotherapy and effective management of associated immune-related adverse events.

Overview

The ICLIO Grand Rounds is an opportunity for ACCC Cancer Program Members to host an ICLIO expert on-site at their program or practice. Customized ICLIO Grand Rounds content will assist your clinicians in their everyday decision-making regarding difficult, real-world cases when treating patients with immuno-oncology (I-O) agents. Applications to host ICLIO Grand Rounds are being accepted through May 31, 2017.

Learning Objectives

The ICLIO Grand Rounds curriculum will be tailored to the needs of the host institution. Learning objectives may include, but are not limited to:

  • A better understanding of the interaction between cancer and the immune system, and evidence supporting the use of cancer immunotherapy to treat specific tumor types.
  • A review of the various mechanisms of action, efficacy, and safety of current and emerging cancer immunotherapies.
  • Effective practices for early recognition and management of immune-related adverse events (irAEs).
  • Discussion of the clinical rationale behind treatment planning decisions.

Two Format Options

Host institutions can select from two ICLIO Grand Rounds format options:

  • 90-minute traditional, case-based tumor board discussion. Presentation of challenging immuno-oncology case(s) (tumor types determined by host institution) by your clinicians and an ICLIO expert. This format features robust discussion of actual de-identified patient cases from the host institution, to help optimize treatment decision-making and enhance clinical reasoning for more effective and efficient care for patients with cancer.
  • 60-minute ICLIO expert-led presentation. An ICLIO faculty expert will present on immuno-oncology topic(s) determined by the host institution. The forum is designed to enhance clinicians’ current knowledge and increase awareness of trends and new findings/indications in immuno-oncology. Sample topics may include:
    • Immunotherapy for the treatment of a specific tumor type
      • General background/current landscape and treatment algorithm
      • Role of immuno-oncology in the specific tumor type
      • Evidence supporting use
      • Challenges and issues
      • Future of immunotherapy for cancer, including immuno-oncology agents in development for the specific tumor type
    • Management of irAEs
    • Current and future role of biomarkers
    • Sequencing of immunotherapies
    • Combination vs. monotherapy immunotherapy
      • Evidence supporting appropriate use
      • Management of irAEs

Who Should Apply?

The ICLIO Grand Rounds are ideal for hospitals or practices interested in optimizing and expanding their immuno-oncology program. To be considered for this exceptional opportunity, we ask that at least 5-10 key members of the host institution’s immuno-oncology program participate/attend in the ICLIO Grand Rounds program.

Participants can include: medical oncologists, hematologists, internists, physician assistants, nurses/nurse practitioners, nurse navigators, pharmacists, fellows, residents, students, and other members of the multidisciplinary cancer care team involved in treating or monitoring patients undergoing immunotherapy at the host institution. In addition to members of the oncology care team who treat patients on a cancer immunotherapy, other clinicians who may care for these patients (e.g., radiology, pathology, gastroenterology, endocrinology, emergency medicine) are welcome to attend the ICLIO Grand Rounds program.

If selected to participate, your cancer program will receive a $1,000 stipend.

Funding for this initiative is provided by a charitable donation from Bristol-Myers Squibb and supported by an educational grant from Merck & Co., Inc.

Application Requirements

To be considered for this opportunity, an institution must meet all of the following criteria:

  • Be a current ACCC Cancer Program Member.*
  • Identify and assign a point of contact (POC) to coordinate plans with the ICLIO Grand Rounds project team.
  • Have already established—or be in the early stages of implementing—an immuno-oncology (I-O) program, and be willing to discuss your I-O program practices with ACCC and ICLIO.
  • Have plans to expand your immuno-oncology program over the next two years.
  • Have a commitment from at least 5-10 key oncology professionals who will participate in the ICLIO Grand Rounds program.
  • If the 90-minute case-based tumor board discussion format is selected, must be willing to discuss de-identified cases with ACCC and ICLIO and have commitment from one clinician to submit an I-O case for discussion.
  • If the 60-minute ICLIO Expert-led format is selected, must have commitment from one clinician to submit an I-O case for discussion.
  • Complete this Grand Rounds application form.
  • Provide permission for ACCC and ICLIO to publish key findings and outcomes from the ICLIO Grand Rounds on their respective websites, as well as in white papers, social media posts, webinars, blogs, newsletters, and live education conferences.

How to Apply

ACCC Cancer Program Members* can apply to participate in the ICLIO Grand Rounds by completing the online application form here, or download PDF application here and email Brissan Guardado. ICLIO Grand Rounds application deadline is May 31, 2017.

*If you are not certain of your membership status, please email Jennifer A. Wilson, MBA, CAE, Membership Director, or call 301.984.9496 ext. 215. You may submit an application for Cancer Program Membership through the ACCC website or via email.

Share: Share on FacebookTweet about this on TwitterShare on LinkedInEmail this to someone